CSPC PHARMA (01093): The Phase I clinical trial of SYH2092 injection for weight management in adults with overweight or obesity has officially launched at the first research center in China.

CSPC PHARMA (01093) announced that the Phase I clinical trial for SYH2092 injection, developed by the group for weight management in adult overweight or obese patients, has officially launched at the first research center in China. This product is an amylin receptor agonist. By optimizing agonistic activity, this product is expected to enhance efficacy while maintaining controllable tolerability. Additionally, through the optimization of fatty acid modifications, the product can extend the in vivo half-life and has the potential to deliver lasting weight loss benefits. Preclinical studies have shown that compared to several amylin analogs currently in clinical development, this product demonstrates higher target agonistic activity, significant weight reduction effects, and sustained weight maintenance. The group received a clinical trial approval notification from the National Medical Products Administration of China for this product in August 2026, and the Phase I clinical trial was initiated following the approval. This Phase I clinical trial aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the product after a single dose in healthy participants. This product is expected to bring significant clinical benefits for weight management in obese patients and improve blood glucose control in adult patients with type 2 diabetes mellitus (T2DM). Recruitment and screening of participants for this Phase I clinical trial are actively progressing.